variability in efficacy and toxicity of medications among patients is largely
attributed to innate differences in their capacity to eliminate and react to
medications. Dr. Lam has studied how ethnicity and genetic differences
affect disposition and response to psychotherapeutic drugs. This has
translated to improved understanding of the biological basis for why patients
require different doses to elicit appropriate responses, particularly
Asians. Dr. Lam’s earlier findings suggested a genetic basis for
variation in drug metabolism and response in Mexican Americans in San
Antonio. His current focus is whether variation in genes that encode
enzymes, transporters, and targets in Hispanics can be utilized for
personalized cancer therapy, and is working with CTRC investigators to integrate
pharmacogenomics into anticancer drug development.
Lam YW. Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacol. 2013;2013:641089.
Lam YW, Ereshefsky L, Port A, Timmer CJ, Dogterom P. Rifampin modulation of the disposition of gepirone and its metabolites. Open Drug Metab J 2009;3:1-7.
Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy. 2002 Aug;22(8):1001-6.
Lam YW, Jann MW, Chang WH, Yu HS, Lin SK, Chen H, Davis CM. Intra- and interethnic variability in reduced haloperidol to haloperidol ratios. J Clin Pharmacol. 1995 Feb;35(2):128-36.
Lam YW, Chang WH, Jann MW, Chen H. Interindividual variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio. Neuropsychopharmacology. 1992 Aug;7(1):33-9.